Merck's Stellar Half-Year Performance: Blockbuster Cancer Drug and HPV Vaccine Dominate

In the first half of 2024, Merck Sharp & Dohme, a world-renowned pharmaceutical giant, delivered a remarkable financial report. According to public data, during this period the company's total revenue reached $31.875 billion, compared with the same period last year increased by 8%, shows its steady business growth. The main drivers of this growth came from its star product in oncology treatment, pembrolizumab, known as drug K, and its HPV vaccine GARDASIL/GARDASIL9.

K, as "the pearl on the crown of" MSD, since 2015, its sales have been maintained strong growth momentum. In the past nine years, created a $101.546 billion K drug accumulative total sales success, become a landmark in the global pharmaceutical industry products. Even on a global scale, an outbreak of the new champions league K drug sales are not affected by the too big, but further narrowed the long dominated with Humira gap of "who" status. By 2023, K medicine success beyond Humira, ascended the throne "who", reveals its leading position in the field of immune therapy.

The success of drug K is no accident, thanks to its broad layout in more than 40 oncology indications, as well as its remarkable efficacy in lung cancer indications. As the PD-1 monoclonal antibody with the most approved indications, drug K has set a new benchmark in scientific research innovation and clinical application.

At the same time, Merck vaccine business also showed strong growth potential. Sales of its HPV vaccine, GARDASIL/GARDASIL9, reached $2.478 billion in the second quarter, up 4% year over year, mainly benefiting from increased demand in the U.S. market. In the first half of the vaccine's total sales reached $4.727 billion, set up a new milestone for global HPV vaccine market. In addition, Merck Sharp & Dohme's 15-valent pneumococcal vaccine Vaxneuvance also performed well, with first-half sales of $408 million, up 49% year over year, and gaining significant market share in the prevention of pneumonia disease.

MSD with tumor K medicine as the core product line, and the vaccine business, successfully promoted the company's overall performance improved, to further consolidate the leading position in the global pharmaceutical industry.